LA JOLLA, Calif.–(BUSINESS WIRE)–EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today the appointment of Franck Brinkhaus, Ph.D., as Chief Financial Officer. EpicentRx recently announced the initiation of the Phase 3 REPLATINUM trial evaluating its lead product candidate RRx-001 for the treatment of third-line and beyond small cell lung cancer (SCLC).
Dr. Brinkhaus is CEO & Founder of Biotech Alliances International, Inc., a Silicon Valley-based life sciences investment bank headed by senior industry advisors with extensive experience in global healthcare market sectors. Dr. Brinkhaus and Biotech Alliances were instrumental in attracting European private financing sources to fund EpicentRx’s recent $35 million Series D round, bringing the company’s total capital raised to approximately $77 million.
“After working with Franck during EpicentRx’s recent financing, it was clear that his experience would be an asset to the company as we move further into late-stage development. His healthcare expertise and financial leadership will assist the company in obtaining the resources needed to develop both our small molecule immunotherapy RRx-001 for SCLC and our oncolytic viral platform,” said Corey A. Carter, M.D., President & CEO of EpicentRx.
“EpicentRx has a unique and compelling approach to treating cancers. I’m excited to join EpicentRx and look forward to working with the management team as the company hits important milestones, including starting a clinical trial of its oncolytic viral program, initiating additional clinical trials of RRx-001 and completing the Phase 3 RRx-001 trial in SCLC,” Dr. Brinkhaus commented.
Previously, Dr. Brinkhaus was Managing Director of Palo Alto-based Woodside Capital Partners, where he specialized in strategic advice, corporate finance, merger & acquisition and capital raising for small and midcap life science companies. He holds a Master’s degree and a Ph.D. in Economics.
About EpicentRx, Inc.
EpicentRx is a patient-driven oncology company developing new mechanisms of immunotherapy that work across diverse patient populations and tumor types with minimal toxicity, enabling the best-possible quality of life during treatment. Through two distinct technology platforms, each targeting a different half of the immune system, the company is developing drug candidates designed to act alone or in combination with other medicines to outsmart cancer. EpicentRx’s lead program is among a portfolio of novel drugs, derived from a class of molecules called dinitroazetidines, that downregulates CD47 – SIRPα to alter the tumor microenvironment and optimize immune response, and has been tested in several clinical trials including an ongoing Phase 3 study in small cell lung cancer. The company is also advancing multiple programs through its smart virus platform, including personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors.
Michelle Linn, Bioscribe, Inc.